目的 探究急性冠狀動脈綜合征（ACS）患者經(jīng)皮冠狀動脈介入治療（PCI）后，采用瑞舒伐他汀短期強化治療對患者心功能、心肌損傷情況及炎癥水平的影響。方法 選擇2015年1月—2017年12月渭南市中醫(yī)醫(yī)院行PCI治療的ACS患者85例，按照入院先后順序分為兩組，對照組（n=43）行抗凝治療、抗血小板治療以及抗血管治療等，根據(jù)患者情況增加血管緊張素轉(zhuǎn)換酶抑制劑或β受體阻滯劑等；觀察組（n=42）在上述基礎(chǔ)上給予瑞舒伐他汀強化治療，每天1次，每次劑量為20 mg，須在睡前進行口服，連續(xù)治療1個月。治療1個月后，觀察患者的心功能、心肌損傷及血清炎癥因子水平等指標。結(jié)果 治療1個月后，兩組治療后左心室射血分數(shù)（LVEF）、房室瓣EA峰比值（E/A）升高，左心室收縮末徑（LVSD）、左心室舒張末徑（LVDD）降低，但差異均無統(tǒng)計學(xué)意義，觀察組心功能指標與對照組無顯著差異。治療1個月后，兩組患者心肌肌鈣蛋白I（cTnI）、肌酸激酶同工酶（CK-MB）均顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組cTnI、CK-MB顯著低于對照組，組間差異有統(tǒng)計學(xué)意義（P<0.05）。治療1個月后，兩組患者腦尿鈉肽（BNP）、超敏C反應(yīng)蛋白（hs-CRP）水平均顯著下降，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組炎癥因子水平明顯低于對照組，組間差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 對行PCI術(shù)后的ACS患者采用瑞舒伐他汀短期強化治療，可有效改善患者心肌損傷情況，降低炎癥水平。

Objective To explore the short-term intensive treatment of rosuvastatin after percutaneous coronary intervention in patients with acute coronary syndromes, and to evaluate the clinical effects of cardiac function, myocardial injury and serum inflammatory factors.Methods the sample was selected as 85 patients with acute coronary syndrome after percutaneous coronary intervention in our hospital, and the choice of time was controlled from January 2015 to December 2017. The randomized digital table was used for group treatment. The control group (n=43) was selected for routine treatment, and the experimental group (n=42) a short-term intensive treatment regimen was selected on the basis of routine treatment in the control group.Results One month after treatment, LVEF, E/A increased, LVSD and LVDD decreased, but there was no significant difference between the two groups. There was no significant difference in cardiac function between the observation group and the control group. One month after treatment, the levels of cTnI and CK-MB in the two groups were significantly higher than those in the control group (P<0.05), and the levels of cTnI and CK-MB in the observation group were significantly lower than those in the control group (P<0.05). One month after treatment, the levels of BNP and hs-CRP in the two groups were significantly decreased, and there was a significant difference between the two groups before and after treatment (P<0.05); and the levels of inflammatory factors in the observation group were significantly lower than those in the control group, the difference was statistically significant (P<0.05).Conclusion the short-term intensive therapy of rosuvastatin after percutaneous coronary intervention in patients with acute coronary syndromes can effectively improve the level of serum inflammatory factors and myocardial injury, which has no effect on cardiac function, so the drug should be very safe.